Product image of Metformina + Pioglitazona Biofarmoz (Metformin Hydrochloride, Pioglitazone) supplied by GNH India

Metformina + Pioglitazona Biofarmoz

Active Ingredient:
Metformin Hydrochloride, Pioglitazone
Origin:
EU

Metformina + Pioglitazona Biofarmoz (Metformin Hydrochloride, Pioglitazone)

Metformin hydrochloride and pioglitazone, the active ingredient in Metformina + Pioglitazona Biofarmoz, is a biguanide; thiazolidinedione presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise and monotherapy are insufficient.
GNH India supplies Metformina + Pioglitazona Biofarmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Biofarmoz- Sociedade Técnico Medicinal, Unipessoal, Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Pioglitazona combines two oral antidiabetic agents to improve glycemic control in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (fasting glucose): lowers fasting plasma glucose levels.
  • Type 2 diabetes mellitus (post‑prandial glucose): reduces post‑prandial glucose excursions.
  • Type 2 diabetes mellitus (combination therapy): enhances overall glycemic control when added to other oral agents or insulin.

How It Works

  • Metformin decreases hepatic gluconeogenesis and increases peripheral glucose uptake, while pioglitazone activates peroxisome proliferator‑activated receptor‑γ (PPARγ) to improve insulin sensitivity in adipose tissue, muscle and liver, together providing complementary glucose‑lowering effects.

Side Effects

The following adverse reactions have been reported with the combination of metformin and pioglitazone.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, often transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild tension‑type headache.
  • Edema: peripheral swelling, especially in the lower limbs.
  • Weight gain: modest increase in body weight.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Hepatic failure: severe liver injury, particularly in patients with pre‑existing liver disease.
  • Congestive heart failure: fluid retention leading to decompensation.
  • Bone fracture: increased risk of femoral fractures with long‑term use.

Precautions & Warnings

When prescribing Metformina + Pioglitazona, clinicians should consider several safety aspects.

  • Renal impairment: assess kidney function before initiation and monitor periodically.
  • Hepatic impairment: avoid in patients with significant liver disease.
  • Lactic acidosis risk: discontinue if signs of hypoxia, severe infection, or acute heart failure occur.
  • Heart failure: use with caution; monitor for signs of fluid overload.
  • Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks.
  • Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Metformina + Pioglitazona may interact with several medicines, requiring clinical attention.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate acute renal failure, increasing metformin accumulation.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): raise pioglitazone plasma levels, heightening toxicity.
  • Insulin or sulfonylureas: combined use can cause severe hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Diuretics: risk of dehydration and renal dysfunction.
  • Corticosteroids: may blunt glucose‑lowering effect, requiring dose adjustment.
  • Beta‑blockers: can mask hypoglycemia symptoms.
  • NSAIDs: may impair renal clearance of metformin.

Frequently Asked Questions

Metformina + Pioglitazona is an oral fixed‑dose combination of metformin and pioglitazone indicated for the treatment of type 2 diabetes mellitus in adults, helping to lower both fasting and post‑prandial blood glucose levels when diet, exercise, or single‑agent therapy are insufficient.

Metformin primarily reduces hepatic glucose production and increases peripheral insulin‑mediated glucose uptake, thereby lowering fasting plasma glucose. In the combination, it works alongside pioglitazone, which enhances insulin sensitivity through PPARγ activation, providing complementary mechanisms to improve overall glycemic control.

The dosage of Metformina + Pioglitazona is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber will select the appropriate strength and dosing schedule.

Safety of Metformina + Pioglitazona in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy, the fixed‑dose combination offers dual mechanisms—metformin’s reduction of hepatic glucose output and pioglitazone’s insulin‑sensitising effect—potentially achieving better glycemic control with a single tablet, whereas separate agents may require multiple pills and dose adjustments.

Store the tablets at temperatures below 25 °C in the original container, protecting them from moisture and direct sunlight. Do not refrigerate or freeze the product.

Metformina + Pioglitazona is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

The most serious risks include lactic acidosis (primarily linked to metformin), hepatic failure, and congestive heart failure or fluid retention (associated with pioglitazone). Patients should be monitored for signs of these conditions and the medication discontinued if they occur.

The combination is contraindicated in patients with severe renal impairment, active liver disease, known hypersensitivity to either component, or a history of lactic acidosis. It should also be avoided in individuals with uncontrolled heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Pioglitazone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT